1. Scrip
  2. >>R&D

BIO Report: Attrition Higher For Novel Pain Candidates Than In Other Diseases, Funding Lacking

 
• By Joseph Haas

A new report released during the BIO CEO conference shows novel pain therapy candidates face a high failure rate, which may help explain why smaller, privately held biotechs aren't very active in the space.

Prescription Opiate and Heroin Abuse

Both the size of the pain drug pipeline and venture capital investment in this space over the past decade pale in comparison with the oncology space, according to a new report, which may be explained by the relatively low rate of success for pain therapeutics.

Novel drug candidates for pain indications advance from Phase I through to approval only 2% of the time compared with 9.6% for novel drug candidates overall, notes the second in a series of reports from the Biotechnology Innovation Organization (BIO) on the state of innovation in highly prevalent chronic diseases. The Volume II: Pain and Addiction Therapeutics report issued during the BIO CEO conference in New York on Feb

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

More from Scrip

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.